Shanghai-based Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.
Latest From Dexter Yan
In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.
Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.